Experimental Dengue Vaccine Protects all Recipients in Human Trials
An experimental dengue vaccine, TV003 that was developed by Dr. Whitehead and his colleagues at NIAID’s Laboratory of Infectious Diseases along with scientists from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research protected 100% of the vaccine recipients in a clinical trial. Volunteers in this trial were infected with dengue virus six months after receiving either the experimental dengue vaccine TV003 or a placebo injection. All 21 volunteers who received the vaccine, were protected from dengue infection, while all 20 placebo recipients developed dengue.
Biotech Connection Singapore
Biotech Connection Singapore (BCS) is part of an international network of non-profit organizations, that aims to promote the transfer of ideas from theory to real world applications by providing a platform for fostering interaction between academia, industry and businesses.
